A Universal Tumor-Specific Promoter for Cancer Gene Therapy

Doklady. Biochemistry and Biophysics
I V AlekseenkoE D Sverdlov

Abstract

An artificial double tandem tumor-specific promoter based on survivin and human telomerase reverse transcriptase gene promoters was constructed. Studies in in vitro and ex vivo therapeutic systems showed that the designed promoter exhibits a high activity in tumor cells, which is comparable to the activity of the CMV constitutive promoter.

References

Aug 2, 2003·Nature Reviews. Cancer·David Kerr
Aug 29, 2003·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·C-P HsuC-Y Chen
Mar 12, 2009·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Armen AzatianReginald V N Lord
May 11, 2010·Expert Review of Vaccines·Kevin S CliveGeorge E Peoples

❮ Previous
Next ❯

Citations

Jul 18, 2019·Head & Neck·Gino MarioniElisabetta Zanoletti
Aug 28, 2020·International Journal of Molecular Sciences·Dina V AntonovaVictor V Pleshkan
Jan 1, 2021·Frontiers in Oncology·Mariela Montaño-SamaniegoMiguel Ibáñez-Hernández
May 8, 2021·International Journal of Toxicology·Ghazale MinaiyanVajihe Akbari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.